Avalo CEO Gary Neill and CFO Chris Sullivan
Avalo Therapeutics shuffles leadership team as the flailing biotech searches for a port in the storm
A badly stumbling public market for biotech has laid waste to small companies in the first weeks of 2022, and now another victim is shuffling …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
